Identification

Name
Linezolid
Accession Number
DB00601  (APRD01073, DB08769)
Type
Small Molecule
Groups
Approved, Investigational
Description

Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.

Structure
Thumb
Synonyms
  • Linezolid
  • Linezolide
  • Linezolidum
  • N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
External IDs
INF 0026 / PNU 100766 / U 100 / U 100766 / U 766 / U-100,766 / U-100766
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LinezolidInjection, solution2 mg/mLIntravenousHospira, Inc.2015-06-18Not applicableUs
LinezolidTablet600 mgOralPanda Pharmaceuticals Inc.Not applicableNot applicableCanada
LinezolidTablet, film coated600 mg/1OralGreenstone, Llc2015-10-12Not applicableUs
Linezolid InjectionSolution2 mgIntravenousNeo Health Canada Inc.Not applicableNot applicableCanada
Linezolid InjectionSolution2 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Linezolid InjectionSolution2 mgIntravenousTeva2014-08-18Not applicableCanada
Linezolid InjectionSolution600 mgIntravenousAuro Pharma IncNot applicableNot applicableCanada
Linezolid InjectionSolution2 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Linezolid InjectionSolution2 mgIntravenousFresenius Kabi2015-06-12Not applicableCanada
Linezolid InjectionSolution2 mgIntravenousMda Inc.Not applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-linezolidTablet600 mgOralApotex Corporation2014-08-19Not applicableCanada
LinezolidInjection, solution2 mg/mLIntravenousHospira, Inc.2015-07-07Not applicableUs
LinezolidTablet, film coated600 mg/1OralAscend Laboratories, LLC2015-12-21Not applicableUs
LinezolidTablet, film coated600 mg/1OralCamber Pharmaceuticals2015-12-21Not applicableUs
LinezolidInjection, solution200 mg/100mLIntravenousSun Pharmaceutical Industries Limited2017-02-01Not applicableUs
LinezolidTablet, film coated600 mg/1OralAv Pak2015-12-31Not applicableUs
LinezolidInjection, solution600 mg/300mLIntravenousSandoz2016-06-15Not applicableUs
LinezolidInjection, solution2 mg/mLIntravenousSagent Pharmaceuticals2017-08-15Not applicableUs
LinezolidTablet, film coated600 mg/1OralMylan Institutional2016-01-22Not applicableUs
LinezolidPowder, for suspension100 mg/5mLOralWest Ward Pharmaceutical2015-06-03Not applicableUs
International/Other Brands
Antizolid (Verisfield) / Linosept (Orion) / Linozid (Orion) / Lizbid (Abbott) / Lizemox (Molekule) / Lizolid (Glenmark) / Xolid (Corona) / Zenix (Hemofarm) / Zizolid (Biofarma) / Zodlin (FDC) / Zolinid (Teva) / Zyvoxid (Pfizer)
Categories
UNII
ISQ9I6J12J
CAS number
165800-03-3
Weight
Average: 337.3461
Monoisotopic: 337.143784348
Chemical Formula
C16H20FN3O4
InChI Key
TYZROVQLWOKYKF-ZDUSSCGKSA-N
InChI
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
IUPAC Name
N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
SMILES
CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1

Pharmacology

Indication

For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.

Associated Conditions
Pharmacodynamics

Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Susceptible organisms include methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely.

Mechanism of action

Linezolid is a synthetic antibacterial agent of the oxazolidinone class of antibiotics. It has in vitro activity against aerobic Gram positive bacteria, certain Gram negative bacteria and anaerobic microorganisms. It selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, linezolid was found to be bactericidal for the majority of strains. Linezolid is also a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.

TargetActionsOrganism
A23S rRNA
inhibitor
Enteric bacteria and other eubacteria
Absorption

Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.

Volume of distribution
  • 40 to 50 L [healthy adult volunteers]
Protein binding

31%

Metabolism

Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite

Route of elimination
Not Available
Half life

4.5-5.5 hours

Clearance
Not Available
Toxicity

Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.

Affected organisms
  • Gram negative and gram positive bacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Linezolid.Experimental
AcebutololLinezolid may increase the hypertensive activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Acetophenazine.Approved
AlaproclateLinezolid may increase the serotonergic activities of Alaproclate.Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Linezolid is combined with Almotriptan.Approved, Investigational
AlosetronAlosetron may increase the serotonergic activities of Linezolid.Approved, Withdrawn
AmineptineLinezolid may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Linezolid is combined with Amisulpride.Approved, Investigational
AmitriptylineLinezolid may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideLinezolid may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmoxapineLinezolid may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Linezolid is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Linezolid.Approved, Illicit, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Linezolid is combined with Aripiprazole.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Linezolid is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Azaperone.Investigational, Vet Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Linezolid.Investigational
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Linezolid.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Linezolid is combined with Benperidol.Approved, Investigational
BenzphetamineLinezolid may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BifeprunoxThe risk or severity of adverse effects can be increased when Linezolid is combined with Bifeprunox.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Linezolid is combined with Brexpiprazole.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Linezolid.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Linezolid is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Linezolid is combined with Bromperidol.Approved, Investigational
BucindololLinezolid may increase the hypertensive activities of Bucindolol.Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Linezolid.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Butaperazine.Experimental
ButriptylineLinezolid may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Linezolid.Approved
CariprazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Cariprazine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Linezolid.Withdrawn
CeliprololLinezolid may increase the hypertensive activities of Celiprolol.Approved, Investigational
ChlorphentermineLinezolid may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CitalopramLinezolid may increase the serotonergic activities of Citalopram.Approved
ClenbuterolLinezolid may increase the hypertensive activities of Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineLinezolid may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Linezolid is combined with Clopenthixol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Linezolid is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Linezolid is combined with Clozapine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Linezolid is combined with Cyclobenzaprine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Linezolid is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Linezolid.Investigational
DesipramineLinezolid may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineLinezolid may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Linezolid.Approved
DibenzepinLinezolid may increase the serotonergic activities of Dibenzepin.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Linezolid.Approved, Investigational
DimetacrineLinezolid may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DixyrazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Dixyrazine.Experimental
DobutamineLinezolid may increase the hypertensive activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Linezolid.Approved, Investigational
DopamineLinezolid may increase the hypertensive activities of Dopamine.Approved
DosulepinLinezolid may increase the serotonergic activities of Dosulepin.Approved
DoxepinLinezolid may increase the serotonergic activities of Doxepin.Approved, Investigational
DroperidolThe risk or severity of adverse effects can be increased when Linezolid is combined with Droperidol.Approved, Vet Approved
DuloxetineLinezolid may increase the serotonergic activities of Duloxetine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Linezolid is combined with Ecopipam.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Linezolid.Approved, Investigational
EpanololLinezolid may increase the hypertensive activities of Epanolol.Experimental
EphedrineLinezolid may increase the hypertensive activities of Ephedrine.Approved
EpinephrineLinezolid may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergotamine.Approved
EscitalopramLinezolid may increase the serotonergic activities of Escitalopram.Approved, Investigational
EtilefrineLinezolid may increase the hypertensive activities of Etilefrine.Withdrawn
EtoperidoneLinezolid may increase the serotonergic activities of Etoperidone.Withdrawn
FencamfamineThe risk or severity of adverse effects can be increased when Linezolid is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolLinezolid may increase the hypertensive activities of Fenoterol.Approved, Investigational
FenozoloneLinezolid may increase the hypertensive activities of Fenozolone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Linezolid is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluanisone.Experimental
FluoxetineLinezolid may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Linezolid is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluspirilene.Approved, Investigational
FluvoxamineLinezolid may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Linezolid is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Linezolid.Approved, Investigational, Vet Approved
GranisetronGranisetron may increase the serotonergic activities of Linezolid.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Linezolid.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Linezolid.Experimental
HydroxyamphetamineLinezolid may increase the hypertensive activities of Hydroxyamphetamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Iloperidone.Approved
ImipramineLinezolid may increase the serotonergic activities of Imipramine.Approved
IndalpineLinezolid may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IprindoleLinezolid may increase the serotonergic activities of Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Linezolid.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Linezolid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Linezolid.Approved
IsoprenalineLinezolid may increase the hypertensive activities of Isoprenaline.Approved, Investigational
IsoxsuprineLinezolid may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
L-TryptophanL-Tryptophan may increase the serotonergic activities of Linezolid.Approved, Nutraceutical, Withdrawn
LabetalolLinezolid may increase the hypertensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Linezolid is combined with Lamotrigine.Approved, Investigational
LevomilnacipranLinezolid may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LipegfilgrastimLinezolid may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Linezolid is combined with Lithium.Approved
LofepramineLinezolid may increase the serotonergic activities of Lofepramine.Experimental
LorcaserinThe risk or severity of adverse effects can be increased when Linezolid is combined with Lorcaserin.Approved
LoxapineThe risk or severity of adverse effects can be increased when Linezolid is combined with Loxapine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Lurasidone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Linezolid is combined with Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Linezolid.Withdrawn
MefenorexLinezolid may increase the hypertensive activities of Mefenorex.Experimental
MelitracenLinezolid may increase the serotonergic activities of Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Melperone.Approved, Investigational
MephentermineLinezolid may increase the hypertensive activities of Mephentermine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Mesoridazine.Approved, Investigational
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Linezolid.Approved, Investigational, Withdrawn
MetaraminolLinezolid may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Linezolid.Approved
MethamphetamineLinezolid may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethotrimeprazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Methotrimeprazine.Approved, Investigational
MethoxamineLinezolid may increase the hypertensive activities of Methoxamine.Approved, Investigational
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Linezolid.Approved, Investigational
MetoclopramideThe risk or severity of adverse effects can be increased when Linezolid is combined with Metoclopramide.Approved, Investigational
MidodrineLinezolid may increase the hypertensive activities of Midodrine.Approved
MilnacipranLinezolid may increase the serotonergic activities of Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Linezolid.Approved
MirtazapineLinezolid may increase the serotonergic activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Linezolid.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Linezolid is combined with Mosapramine.Experimental
NaratriptanThe risk or severity of adverse effects can be increased when Linezolid is combined with Naratriptan.Approved, Investigational
NefazodoneLinezolid may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Linezolid.Withdrawn
NorepinephrineLinezolid may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineLinezolid may increase the serotonergic activities of Nortriptyline.Approved
NylidrinLinezolid may increase the hypertensive activities of Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Linezolid.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine.Approved, Investigational
OndansetronOndansetron may increase the serotonergic activities of Linezolid.Approved
OpipramolLinezolid may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineLinezolid may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Linezolid is combined with Osanetant.Investigational
OxymetazolineLinezolid may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxypertineThe risk or severity of adverse effects can be increased when Linezolid is combined with Oxypertine.Experimental
PaliperidoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Linezolid.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Linezolid.Approved
ParoxetineLinezolid may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Linezolid is combined with Penfluridol.Experimental
PerazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Linezolid is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Linezolid.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Linezolid.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Linezolid.Withdrawn
PhenmetrazineLinezolid may increase the hypertensive activities of Phenmetrazine.Approved, Illicit
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Linezolid.Withdrawn
PhentermineLinezolid may increase the hypertensive activities of Phentermine.Approved, Illicit
PhenylephrineLinezolid may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineLinezolid may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Linezolid.Approved
PimozideThe risk or severity of adverse effects can be increased when Linezolid is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Pipotiazine.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Linezolid.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Linezolid.Withdrawn
PrenalterolLinezolid may increase the hypertensive activities of Prenalterol.Experimental
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Linezolid.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Linezolid.Approved, Investigational
ProcaterolLinezolid may increase the hypertensive activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Promethazine.Approved, Investigational
PropericiazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Propericiazine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Linezolid is combined with Prothipendyl.Investigational
ProtriptylineLinezolid may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineLinezolid may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Linezolid is combined with Quetiapine.Approved
RacepinephrineLinezolid may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Linezolid is combined with Raclopride.Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Linezolid.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Linezolid is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Linezolid is combined with Reserpine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Linezolid is combined with Ritanserin.Investigational
RitodrineLinezolid may increase the hypertensive activities of Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Linezolid is combined with Rizatriptan.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Linezolid.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Linezolid.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Linezolid is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineLinezolid may increase the serotonergic activities of Sertraline.Approved
SulpirideThe risk or severity of adverse effects can be increased when Linezolid is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Linezolid is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Linezolid is combined with Sumatriptan.Approved, Investigational
SynephrineLinezolid may increase the hypertensive activities of Synephrine.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Linezolid is combined with Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Linezolid.Approved
TerbutalineLinezolid may increase the hypertensive activities of Terbutaline.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Linezolid is combined with Tetrahydropalmatine.Investigational
TetryzolineLinezolid may increase the hypertensive activities of Tetryzoline.Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Linezolid is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Linezolid is combined with Thiothixene.Approved
TianeptineLinezolid may increase the serotonergic activities of Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Linezolid is combined with Tiapride.Approved, Investigational
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Linezolid.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Linezolid.Approved, Investigational
TramazolineLinezolid may increase the hypertensive activities of Tramazoline.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Linezolid.Approved, Investigational
TrazodoneLinezolid may increase the serotonergic activities of Trazodone.Approved, Investigational
TretoquinolLinezolid may increase the hypertensive activities of Tretoquinol.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Linezolid is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Linezolid is combined with Triflupromazine.Approved, Vet Approved
TrimipramineLinezolid may increase the serotonergic activities of Trimipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Linezolid.Approved, Investigational
TyramineLinezolid may increase the hypertensive activities of Tyramine.Investigational, Nutraceutical
VenlafaxineLinezolid may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Linezolid is combined with Veralipride.Experimental
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Linezolid.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Linezolid.Approved, Investigational
ZimelidineLinezolid may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Linezolid.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Linezolid is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Linezolid is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference
US5688792
General References
  1. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother. 2006 Sep;58(3):701-4. Epub 2006 Jul 19. [PubMed:16857689]
External Links
Human Metabolome Database
HMDB0014739
KEGG Drug
D00947
KEGG Compound
C08146
PubChem Compound
441401
PubChem Substance
46504452
ChemSpider
390139
BindingDB
50116067
ChEBI
63607
ChEMBL
CHEMBL126
Therapeutic Targets Database
DAP000398
PharmGKB
PA450233
HET
ZLD
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Linezolid
ATC Codes
J01XX08 — Linezolid
AHFS Codes
  • 08:12.28.24 — Oxazolidinones
PDB Entries
3cpw / 3dll / 4k7q / 4wfa / 5nz0
FDA label
Download (106 KB)
MSDS
Download (43.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableTuberculosis1
1CompletedBasic ScienceBacterial Infections1
1CompletedBasic ScienceGram Positive Infection1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentMinor burns1
1WithdrawnPreventionNeurosurgery1
1WithdrawnTreatmentBacterial Infections1
1, 2CompletedTreatmentExtensively Drug Resistant Tuberculosis / Multi-Drug Resistant Tuberculosis2
1, 2CompletedTreatmentTB Multi-drug Resistant1
2Active Not RecruitingTreatmentTuberculosis, Pulmonary1
2CompletedTreatmentAbscesses / Bacterial Skin Diseases / Infectious Skin Diseases / Staphylococcal Skin Infections / Streptococcal Infections1
2CompletedTreatmentAcute Bacterial Skin and Skin Structure Infections1
2CompletedTreatmentBacterial Infections3
2CompletedTreatmentExtensively Drug Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2CompletedTreatmentSkin Diseases, Bacterial1
2CompletedTreatmentSkin Infections, Bacterial1
2CompletedTreatmentSkin and Subcutaneous Tissue Bacterial Infections2
2Not Yet RecruitingTreatmentLinezolid / Tuberculous Meningitis1
2RecruitingTreatmentTuberculosis, Multidrug Resistant1
2RecruitingTreatmentTuberculosis, Pulmonary1
2TerminatedTreatmentInfected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee1
2TerminatedTreatmentNeoplasms / Neutropenia, Febrile1
2TerminatedTreatmentOsteomyelitis1
2Unknown StatusNot AvailableCystic Fibrosis (CF)1
2Unknown StatusTreatmentHip Prosthetic Joint Infection1
2Unknown StatusTreatmentPulmonary Tuberculosis Without Resistance to Rifampicin1
2, 3Not Yet RecruitingTreatmentTuberculosis, Pulmonary1
2, 3RecruitingTreatmentExtensively Drug-Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2, 3RecruitingTreatmentExtensively-drug Resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
3Active Not RecruitingTreatmentPneumonia1
3Active Not RecruitingTreatmentTuberculosis, Pulmonary1
3CompletedTreatmentAbscesses / Cellulitis / Surgical Site Infections / Wound Infections2
3CompletedTreatmentAcute Bacterial Skin and Skin Structure Infections1
3CompletedTreatmentBacteremia / Bacterial Infections / Infections, Gram-Positive Bacterial1
3CompletedTreatmentBacterial Infections2
3CompletedTreatmentBacterial Infections / Skin Structures and Soft Tissue Infections2
3CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
3CompletedTreatmentHospital Acquired Infections1
3CompletedTreatmentNeutropenia, Febrile1
3CompletedTreatmentSkin Diseases, Bacterial1
3CompletedTreatmentSkin Diseases, Infectious1
3CompletedTreatmentSkin Infections, Bacterial1
3CompletedTreatmentSkin and Subcutaneous Tissue Bacterial Infections2
3RecruitingTreatmentAcute Bacterial Skin and Skin Structure Infections1
3RecruitingTreatmentCommunity Acquired Bacterial Pneumonia / Community Acquired Pneumonia (CAP)1
3RecruitingTreatmentExtensively Drug-Resistant Tuberculosis / Pre-XDR-TB / Tuberculosis / Tuberculosis, MDR / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
3RecruitingTreatmentHealthcare-associated Pneumonia (HCAP) / Hospital-acquired bacterial pneumonia / Ventilator-associated Bacterial Pneumonia1
3RecruitingTreatmentPneumonia, Bacterial1
3RecruitingTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious1
3RecruitingTreatmentStaphylococcus Aureus Infections1
3RecruitingTreatmentTuberculosis, Multidrug Resistant1
3TerminatedNot AvailableOptic Nerve Diseases1
3TerminatedTreatmentBacteremia / Infections, Gram-Positive Bacterial1
3TerminatedTreatmentSkin Diseases, Infectious1
3WithdrawnTreatmentCommunity Acquired Pneumonia (CAP)1
3WithdrawnTreatmentSkin Structures and Soft Tissue Infections1
3WithdrawnTreatmentTuberculosis Multi Drug Resistant Active1
4CompletedNot AvailableComplicated Skin and Structure Infection / Hospital-acquired bacterial pneumonia1
4CompletedTreatmentInfections, Gram-Positive Bacterial / Skin and Connective Tissue Diseases1
4CompletedTreatmentMRSA Infection1
4CompletedTreatmentMethicillin Resistant Staphylococcus Aureus (MRSA)1
4CompletedTreatmentMethicillin Resistant Staphylococcus Aureus (MRSA) / Skin/Soft Tissue Infections1
4CompletedTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA)1
4CompletedTreatmentVentilator-Associated Pneumonia (VAP)1
4RecruitingNot AvailablePneumonia1
4RecruitingTreatmentCritical Illness / Mechanical Ventilation Complication1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedNot AvailableBacteremia / Pneumonia1
4TerminatedPreventionAcute Bacterial Skin and Skin Structure Infections / Bacteremia / Endocarditis / Health Care Associated Pneumonia / Osteomyelitis/Septic Arthritis1
4WithdrawnNot AvailableVentilator Acquired Pneumonia1
Not AvailableCompletedNot AvailableImpaired Renal Function / Renal Failure1
Not AvailableCompletedNot AvailableInfection caused by staphylococci1
Not AvailableCompletedNot AvailableInfections, Gram-Positive Bacterial1
Not AvailableCompletedNot AvailableMethicillin-Resistant Staphylococcus Aureus (MRSA) / Pneumonia, Hospital-Acquired1
Not AvailableCompletedNot AvailablePneumonia1
Not AvailableCompletedNot AvailableSepsis1
Not AvailableCompletedNot AvailableVancomycin Resistance Enterococcus Faecium1
Not AvailableCompletedTreatmentAbscesses / Skin Diseases, Bacterial1
Not AvailableCompletedTreatmentInfection caused by staphylococci / Infections, Gram-Positive Bacterial1
Not AvailableRecruitingNot AvailableAbscesses / Cellulitis / Erysipelas / Wound Infections1
Not AvailableRecruitingNot AvailableCritical Illness / Infection NOS1
Not AvailableRecruitingOtherTuberculosis1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
Packagers
  • Fresenius Kabi AB
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Pfizer Inc.
  • Pharmacia Inc.
Dosage forms
FormRouteStrength
Injection, solutionIntravenous2 mg/mL
Injection, solutionIntravenous200 mg/100mL
Injection, solutionIntravenous600 mg/300mL
Powder, for suspensionOral100 mg/5mL
TabletOral600 mg/1
Tablet, film coatedOral600 mg/1
SolutionIntravenous600 mg
InjectionIntravenous600 mg/300mL
Injection, solutionIntravenous400 mg/200mL
SuspensionOral100 mg/5mL
Powder, for suspensionOral3 g
SolutionIntravenous2 mg
TabletOral600 mg
Prices
Unit descriptionCostUnit
Zyvox 600 mg tablet93.81USD tablet
Zyvox 200 mg/100 ml iv soln0.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5688792No1994-11-182014-11-18Us
CA2168560No2001-08-142014-08-16Canada
US6559305Yes2001-07-292021-07-29Us
US6514529Yes2001-09-152021-09-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility3 mg/mLNot Available
logP0.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.44 mg/mLALOGPS
logP0.61ALOGPS
logP0.64ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.45ChemAxon
pKa (Strongest Basic)-0.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.11 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity84.47 m3·mol-1ChemAxon
Polarizability34.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9363
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.5881
P-glycoprotein inhibitor IInhibitor0.7599
P-glycoprotein inhibitor IINon-inhibitor0.6478
Renal organic cation transporterNon-inhibitor0.7469
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5904
CYP450 1A2 substrateNon-inhibitor0.7811
CYP450 2C9 inhibitorNon-inhibitor0.8174
CYP450 2D6 inhibitorNon-inhibitor0.8112
CYP450 2C19 inhibitorNon-inhibitor0.5664
CYP450 3A4 inhibitorNon-inhibitor0.7563
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5544
Ames testNon AMES toxic0.6839
CarcinogenicityNon-carcinogens0.8916
BiodegradationNot ready biodegradable0.9895
Rat acute toxicity2.4938 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7883
hERG inhibition (predictor II)Inhibitor0.6297
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0009000000-05a0d0b23e80851df1d5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000j-0396000000-959c643931df034e05fc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000b-0940000000-066fc762e228726946fb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0292-0900000000-99847141a31b0134dcfa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000j-0900000000-7cf676c358a3890ab460
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000j-0900000000-fdccf108eb9fcb8a102d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-1649000000-a1dedd5c256e9f3bfa4f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0649000000-1ac199ac8af65a2644f8

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Phenylmorpholines
Alternative Parents
Aniline and substituted anilines / Dialkylarylamines / Fluorobenzenes / Oxazolidinones / Aryl fluorides / Acetamides / Carbamate esters / Secondary carboxylic acid amides / Organic carbonic acids and derivatives / Dialkyl ethers
show 7 more
Substituents
Phenylmorpholine / Aniline or substituted anilines / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Oxazolidinone
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, acetamides, morpholines, oxazolidinone (CHEBI:63607)

Targets

1. 23S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sinclair A, Arnold C, Woodford N: Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci. Antimicrob Agents Chemother. 2003 Nov;47(11):3620-2. [PubMed:14576130]
  4. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC Jr, Gold HS: Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis. 2004 Jul 15;190(2):311-7. Epub 2004 Jun 9. [PubMed:15216466]
  5. Zhu W, Tenover FC, Limor J, Lonsway D, Prince D, Dunne WM Jr, Patel JB: Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis. 2007 Mar;26(3):161-5. [PubMed:17393201]
  6. Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund ET, Cavey GS, Mathews WR, Adams LD, Cecil ET, Pearson JD, Bock JH, Mott JE, Shinabarger DL, Xiong L, Mankin AS: Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003 Jun 13;278(24):21972-9. Epub 2003 Apr 10. [PubMed:12690106]
  7. Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Legare D, Ouellette M: Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23. doi: 10.1101/gr.089342.108. Epub 2009 Apr 6. [PubMed:19351617]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Stevens DL, Dotter B, Madaras-Kelly K: A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther. 2004 Feb;2(1):51-9. [PubMed:15482171]
  2. Taylor JJ, Wilson JW, Estes LL: Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006 Jul 15;43(2):180-7. Epub 2006 Jun 9. [PubMed:16779744]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Stevens DL, Dotter B, Madaras-Kelly K: A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther. 2004 Feb;2(1):51-9. [PubMed:15482171]
  2. Taylor JJ, Wilson JW, Estes LL: Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006 Jul 15;43(2):180-7. Epub 2006 Jun 9. [PubMed:16779744]

Drug created on June 13, 2005 07:24 / Updated on June 20, 2018 23:52